CareFusion AVEA Ventilator Recall Issued Due to Risk of Failure

|

After receiving nearly a hundred reports of malfunctions, CareFusion has recalled its AVEA Ventilator from the market. 

The FDA announced the CareFusion AVEA ventilator recall on December 23, indicating that a defective alarm may actually shut the ventilator down.

Due to the seriousness of the malfunction, the FDA has classified the action as a Class I medical device recall, which is the most serious classification. A Class I recall indicates that the FDA believes the device has a high chance of causing serious injury or death.

Sports-Betting-Addiction-Lawsuits
Sports-Betting-Addiction-Lawsuits

According to the FDA, the AVEA ventilator has been reported to activate a false, extended high peak alarm, which then opens the safety valve and stops ventilating.

The problem could injure or kill a patient without a health care professional’s intervention. Although there have been no reported injuries or deaths associated with the product so far, CareFusion has received at least 94 reports of incidents where the ventilators stopped working.

CareFusion sent out letters to customers in September, but the FDA did not become aware of the situation until recently, resulting in the Class I recall.

The recall affects all models of the CareFusion AVEA ventilator manufactured between March 1, 2009 and June 30, 2011, as well as any AVEA ventilators serviced with affected parts during that time period.

The company sent out letters to all affected customers and contacted them by telephone to coordinate corrective actions.

The FDA has called for any health care professionals or patients who have experienced problems due to this device to contact the FDA MedWatch Adverse Event Reporting program at www.fda.gov/medwatch or by calling (800) FDA-1088.


0 Comments


This field is for validation purposes and should be left unchanged.

Share Your Comments

This field is hidden when viewing the form
I authorize the above comments be posted on this page
Post Comment
Weekly Digest Opt-In

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

MORE TOP STORIES

A group of plaintiffs has petitioned the U.S. Judicial Panel on Multidistrict Litigation to centralize all Dupixent lymphoma lawsuits before a single judge for coordinated pretrial proceedings, a move that could ultimately lead to bellwether trials and a global resolution of the claims.
Bayer and Monsanto say they have reached a $7.25 billion Roundup cancer lawsuit settlement resolving more than 100,000 claims as well as any future litigation that may be filed.
A federal judge is allowing direct filing of Roblox sex abuse lawsuits with the MDL court and will allow both survivors and guardians to file anonymously.